Ono Pharmaceutical . Stock Earnings Reports

ONO Pharmaceutical reported Q1 FY2026 core results with revenue of JPY127.5 billion (up JPY9.9 billion, +8.4% YoY), the highest Q1 sales on record. Growth was driven by the inclusion of Deciphera (QINLOCK and ROMVIMZA) and continued strength in FORXIGA, while domestic OPDIVO sales declined due to intensifying competition. Core operating profit fell to JPY31.6 billion (down JPY3.5 billion, -10.1% YoY), primarily because Deciphera contributed an operating loss in the period; excluding Deciphera the business showed modest profit improvement. The company left full-year guidance unchanged. Key commercial priorities: defend and rebuild OPDIVO market share (focus on gastric cancer — target 70% new-prescription share by year-end — and recover lung cancer share via PD-L1-negative positioning and new indications), leverage new Deciphera products to exceed overseas sales targets, and integrate newly licensed assets. Pipeline and regulatory updates: approvals and filings progressing (OPDIVO+YERVOY added for first-line hepatocellular carcinoma in Japan, Korea, Taiwan; ROMVIMZA positive opinion in Europe), some timing shifts for bladder cancer and adjuvant hepatocellular carcinoma filings to next fiscal year, discontinuation of ONO-7475 for strategic reasons, and new in-licenses including povetacicept (BAFF/APRIL dual antagonist) for Japan/South Korea with Phase III for IgA nephropathy ongoing. Other notable programs: sapablursen acquisition progressing into development, multiple oncology and non-oncology mid-stage readouts expected (several key data points anticipated this autumn), and the company plans to prioritize late-stage assets while using compact, biomarker-driven early trials to make efficient Go/No-Go decisions.